188 related articles for article (PubMed ID: 28196297)
21. Metabolic features of melanoma: a gold mine of new therapeutic targets?
Marchetti P; Guerreschi P; Kluza J; Mortier L
Curr Cancer Drug Targets; 2014; 14(4):357-70. PubMed ID: 24720363
[TBL] [Abstract][Full Text] [Related]
22. New drug targets in metastatic melanoma.
Homet B; Ribas A
J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
[TBL] [Abstract][Full Text] [Related]
23. Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion.
Kääriäinen E; Nummela P; Soikkeli J; Yin M; Lukk M; Jahkola T; Virolainen S; Ora A; Ukkonen E; Saksela O; Hölttä E
J Pathol; 2006 Oct; 210(2):181-91. PubMed ID: 16924594
[TBL] [Abstract][Full Text] [Related]
24. Role of β-catenin signaling in the anti-invasive effect of the omega-3 fatty acid DHA in human melanoma cells.
Serini S; Zinzi A; Ottes Vasconcelos R; Fasano E; Riillo MG; Celleno L; Trombino S; Cassano R; Calviello G
J Dermatol Sci; 2016 Nov; 84(2):149-159. PubMed ID: 27600927
[TBL] [Abstract][Full Text] [Related]
25. Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype.
Sinnberg T; Levesque MP; Krochmann J; Cheng PF; Ikenberg K; Meraz-Torres F; Niessner H; Garbe C; Busch C
Mol Cancer; 2018 Feb; 17(1):59. PubMed ID: 29454361
[TBL] [Abstract][Full Text] [Related]
26. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
[TBL] [Abstract][Full Text] [Related]
27. Lebein, a Snake Venom Disintegrin, Induces Apoptosis in Human Melanoma Cells.
Hammouda MB; Montenegro MF; Sánchez-Del-Campo L; Zakraoui O; Aloui Z; Riahi-Chebbi I; Karoui H; Rodríguez-López JN; Essafi-Benkhadir K
Toxins (Basel); 2016 Jul; 8(7):. PubMed ID: 27399772
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.
O'Connell MP; Marchbank K; Webster MR; Valiga AA; Kaur A; Vultur A; Li L; Herlyn M; Villanueva J; Liu Q; Yin X; Widura S; Nelson J; Ruiz N; Camilli TC; Indig FE; Flaherty KT; Wargo JA; Frederick DT; Cooper ZA; Nair S; Amaravadi RK; Schuchter LM; Karakousis GC; Xu W; Xu X; Weeraratna AT
Cancer Discov; 2013 Dec; 3(12):1378-93. PubMed ID: 24104062
[TBL] [Abstract][Full Text] [Related]
29. Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing.
Miskolczi Z; Smith MP; Rowling EJ; Ferguson J; Barriuso J; Wellbrock C
Oncogene; 2018 Jun; 37(23):3166-3182. PubMed ID: 29545604
[TBL] [Abstract][Full Text] [Related]
30. The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report.
Eichhoff OM; Zipser MC; Xu M; Weeraratna AT; Mihic D; Dummer R; Hoek KS
Melanoma Res; 2010 Aug; 20(4):349-55. PubMed ID: 20526217
[TBL] [Abstract][Full Text] [Related]
31. Microphthalmia-associated transcription factor expression levels in melanoma cells contribute to cell invasion and proliferation.
Vachtenheim J; Ondrušová L
Exp Dermatol; 2015 Jul; 24(7):481-4. PubMed ID: 25866058
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines.
Noguchi K; Dalton AC; Howley BV; McCall BJ; Yoshida A; Diehl JA; Howe PH
PLoS One; 2017; 12(5):e0177830. PubMed ID: 28545079
[TBL] [Abstract][Full Text] [Related]
33. Nivolumab success in untreated metastatic melanoma.
Wilkinson E
Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638562
[No Abstract] [Full Text] [Related]
34. Melanoma spheroids grown under neural crest cell conditions are highly plastic migratory/invasive tumor cells endowed with immunomodulator function.
Ramgolam K; Lauriol J; Lalou C; Lauden L; Michel L; de la Grange P; Khatib AM; Aoudjit F; Charron D; Alcaide-Loridan C; Al-Daccak R
PLoS One; 2011 Apr; 6(4):e18784. PubMed ID: 21526207
[TBL] [Abstract][Full Text] [Related]
35. Melanoma epigenetics: novel mechanisms, markers, and medicines.
Lee JJ; Murphy GF; Lian CG
Lab Invest; 2014 Aug; 94(8):822-38. PubMed ID: 24978641
[TBL] [Abstract][Full Text] [Related]
36. PPAR gamma regulates MITF and beta-catenin expression and promotes a differentiated phenotype in mouse melanoma S91.
Grabacka M; Placha W; Urbanska K; Laidler P; Płonka PM; Reiss K
Pigment Cell Melanoma Res; 2008 Jun; 21(3):388-96. PubMed ID: 18444964
[TBL] [Abstract][Full Text] [Related]
37. Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma.
Zhang C; Smalley I; Emmons MF; Sharma R; Izumi V; Messina J; Koomen JM; Pasquale EB; Forsyth PA; Smalley KSM
J Invest Dermatol; 2021 Apr; 141(4):840-851.e4. PubMed ID: 32890629
[TBL] [Abstract][Full Text] [Related]
38. The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1.
Mathieu MG; Miles AK; Ahmad M; Buczek ME; Pockley AG; Rees RC; Regad T
Cell Death Dis; 2014 Feb; 5(2):e1061. PubMed ID: 24525737
[TBL] [Abstract][Full Text] [Related]
39. Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights.
Xue G; Romano E; Massi D; Mandalà M
Cancer Treat Rev; 2016 Sep; 49():1-12. PubMed ID: 27395773
[TBL] [Abstract][Full Text] [Related]
40. Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?
Kim KB
Cancer; 2013 Feb; 119(3):477-80. PubMed ID: 22915026
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
